NZ600268A - Method to use gene expression to determine likelihood of clinical outcome of renal cancer - Google Patents

Method to use gene expression to determine likelihood of clinical outcome of renal cancer

Info

Publication number
NZ600268A
NZ600268A NZ600268A NZ60026811A NZ600268A NZ 600268 A NZ600268 A NZ 600268A NZ 600268 A NZ600268 A NZ 600268A NZ 60026811 A NZ60026811 A NZ 60026811A NZ 600268 A NZ600268 A NZ 600268A
Authority
NZ
New Zealand
Prior art keywords
cell carcinoma
renal cell
ppap2b
recurrence
likelihood
Prior art date
Application number
NZ600268A
Other languages
English (en)
Inventor
Steven Shak
Michael C Kiefer
Frederick L Baehner
Dejan Knezevic
Tara Maddala
Audrey Goddard
Wayne Cowens
Joffre Baker
Original Assignee
Genomic Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc filed Critical Genomic Health Inc
Priority to NZ61700311A priority Critical patent/NZ617003A/en
Publication of NZ600268A publication Critical patent/NZ600268A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N7/00—Computing arrangements based on specific mathematical models
    • G06N7/01—Probabilistic graphical models, e.g. probabilistic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B99/00—Subject matter not provided for in other groups of this subclass
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Data Mining & Analysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Mathematical Analysis (AREA)
  • Artificial Intelligence (AREA)
  • Probability & Statistics with Applications (AREA)
  • Algebra (AREA)
  • Computational Mathematics (AREA)
NZ600268A 2010-01-11 2011-01-07 Method to use gene expression to determine likelihood of clinical outcome of renal cancer NZ600268A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ61700311A NZ617003A (en) 2010-01-11 2011-01-07 Method to use gene expression to determine likelihood of clinical outcome of renal cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29403810P 2010-01-11 2010-01-11
US34623010P 2010-05-19 2010-05-19
PCT/US2011/020596 WO2011085263A2 (en) 2010-01-11 2011-01-07 Method to use gene expression to determine likelihood of clinical outcome of renal cancer

Publications (1)

Publication Number Publication Date
NZ600268A true NZ600268A (en) 2014-08-29

Family

ID=44258831

Family Applications (4)

Application Number Title Priority Date Filing Date
NZ600268A NZ600268A (en) 2010-01-11 2011-01-07 Method to use gene expression to determine likelihood of clinical outcome of renal cancer
NZ719474A NZ719474A (en) 2010-01-11 2011-01-07 Method to use gene expression to determine likelihood of clinical outcome of renal cancer
NZ705645A NZ705645A (en) 2010-01-11 2011-01-07 Method to use gene expression to determine likelihood of clinical outcome of renal cancer
NZ61700311A NZ617003A (en) 2010-01-11 2011-01-07 Method to use gene expression to determine likelihood of clinical outcome of renal cancer

Family Applications After (3)

Application Number Title Priority Date Filing Date
NZ719474A NZ719474A (en) 2010-01-11 2011-01-07 Method to use gene expression to determine likelihood of clinical outcome of renal cancer
NZ705645A NZ705645A (en) 2010-01-11 2011-01-07 Method to use gene expression to determine likelihood of clinical outcome of renal cancer
NZ61700311A NZ617003A (en) 2010-01-11 2011-01-07 Method to use gene expression to determine likelihood of clinical outcome of renal cancer

Country Status (12)

Country Link
US (4) US9551034B2 (enExample)
EP (5) EP3029155A3 (enExample)
JP (5) JP6286124B2 (enExample)
AU (1) AU2011203977B2 (enExample)
CA (3) CA3128103C (enExample)
DK (1) DK3178944T3 (enExample)
ES (2) ES3027507T3 (enExample)
IL (6) IL219978A (enExample)
MX (3) MX341866B (enExample)
NZ (4) NZ600268A (enExample)
SG (1) SG181806A1 (enExample)
WO (1) WO2011085263A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3027507T3 (en) 2010-01-11 2025-06-16 Genomic Health Inc Method to use gene expression to determine likelihood of clinical outcome of renal cancer
DK2598659T3 (en) 2010-07-27 2015-05-26 Genomic Health Inc PROCEDURE FOR USING GENEPRESSION FOR DETERMINING PROSTATE CANCER FORECAST
EP2603622A4 (en) 2010-08-13 2015-04-22 Somalogic Inc BIOMARKERS FOR PANCREATIC CANCER AND USES THEREOF
WO2013016673A2 (en) * 2011-07-27 2013-01-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of dpep1 and tpx2 expression for evaluating treatment or survival time of patients with pancreatic ductal adenocarcinoma
EP2748356A2 (en) * 2011-08-22 2014-07-02 Somalogic, Inc. Renal cell carcinoma biomarkers and uses thereof
HK1212389A1 (en) 2011-10-24 2016-06-10 Signalchem Lifesciences Corporation Carbonic anhydrase ix-related markers and use thereof
CA2863040C (en) 2012-01-31 2022-04-19 Genomic Health, Inc. Gene expression profile algorithm and test for determining prognosis of prostate cancer
CA2903878C (en) * 2013-05-30 2020-10-27 Genomic Health, Inc. Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
WO2015050500A1 (en) 2013-09-17 2015-04-09 Agency For Science, Technology And Research Multigene assay for prognosis of renal cancer
US10731163B2 (en) * 2014-09-02 2020-08-04 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Oligonucleotide targeted to the A20-3′ untranslated region
JP6638128B2 (ja) * 2014-10-30 2020-01-29 公立大学法人福島県立医科大学 腎がんの悪性度の検査マーカー及び検査方法
US20180044736A1 (en) * 2015-02-03 2018-02-15 Cedars-Sinai Medical Center Biomarker based prognostic model for predicting overall survival in patients with metastatic clear cell kidney cancer
GB201616912D0 (en) 2016-10-05 2016-11-16 University Of East Anglia Classification of cancer
CA3052670A1 (en) 2017-03-01 2018-09-07 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2018161027A1 (en) * 2017-03-03 2018-09-07 Oregon State University Antisense antibacterial compounds and methods
US10636512B2 (en) 2017-07-14 2020-04-28 Cofactor Genomics, Inc. Immuno-oncology applications using next generation sequencing
US11335464B2 (en) * 2018-01-12 2022-05-17 Siemens Medical Solutions Usa, Inc. Integrated precision medicine by combining quantitative imaging techniques with quantitative genomics for improved decision making
CA3105292A1 (en) * 2018-08-10 2020-02-13 Omniseq, Inc. Methods and systems for assessing proliferative potential and resistance to immune checkpoint blockade
WO2020085936A1 (ru) * 2018-10-24 2020-04-30 Общество С Ограниченной Ответственностью "Онкобокс" Тест-классификатор клинического ответа на лечение сорафенибом индивидуальных пациентов с раком почки
MX2021008797A (es) 2019-01-23 2022-01-31 Regeneron Pharma Tratamiento de afecciones oftalmicas con inhibidores de proteinas relacionadas a angiopoyetina 7 (angptl7).
US11845989B2 (en) 2019-01-23 2023-12-19 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
US20220364178A1 (en) * 2019-08-14 2022-11-17 University Of Massachusetts Urinary rna signatures in renal cell carcinoma (rcc)
EP4298219A1 (en) 2021-02-26 2024-01-03 Regeneron Pharmaceuticals, Inc. Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (angptl7) inhibitors
CN113025716A (zh) * 2021-03-02 2021-06-25 北京大学第一医院 一种用于人肿瘤分级的基因组合及其用途
CN113817816A (zh) * 2021-10-08 2021-12-21 济南艾迪康医学检验中心有限公司 检测epas1基因突变的引物、试剂盒和方法
WO2023080900A1 (en) * 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
CN118711678B (zh) * 2024-08-22 2025-12-12 暨南大学附属第一医院（广州华侨医院） 一种肾透明细胞肿瘤预测方法、装置、设备及存储介质

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US7135314B1 (en) 1997-04-17 2006-11-14 Cell Therapeutics, Inc. Human phosphatidic acid phosphatase
DE60137829D1 (de) * 2000-01-13 2009-04-16 Genentech Inc Menschliche stra6 polypeptide
DE10126344A1 (de) 2000-07-14 2002-01-24 Max Planck Gesellschaft Apoptose-induzierende DNA-Sequenzen
AU2001294842A1 (en) * 2000-09-28 2002-04-08 Atairgin Technologies, Inc. A method of determining tumor characteristics by determining abnormal copy number or expression level of lipid-associated genes
AU2002254482A1 (en) * 2001-03-19 2002-10-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of kidney cancer
WO2002079411A2 (en) * 2001-03-29 2002-10-10 Van Andel Institute Microarray gene expression profiling in clear cell renal cell carcinoma: prognosis and drug target identification
DE60239535D1 (de) 2001-06-18 2011-05-05 Rosetta Inpharmatics Llc Diagnose und prognose von brustkrebspatientinnen
US7470509B2 (en) * 2002-02-08 2008-12-30 Millennium Pharmaceuticals, Inc. Compositions and methods for the identification, assessment, prevention and therapy of ovarian cancer
DK2258872T3 (da) 2002-03-13 2013-11-18 Genomic Health Inc Genekspressionsprofilering i biopsier af tumorvæv
US20060183120A1 (en) 2002-10-04 2006-08-17 Teh Bin T Molecular sub-classification of kidney tumors and the discovery of new diagnostic markers
AU2003298689A1 (en) 2002-11-21 2004-06-18 Wyeth Methods for diagnosing rcc and other solid tumors
CA2523798A1 (en) 2003-04-29 2004-11-11 Wyeth Methods for prognosis and treatment of solid tumors
EP3170906B1 (en) 2003-06-24 2018-08-22 Genomic Health, Inc. Prediction of likelihood of cancer recurrence
EP1644522A2 (en) 2003-07-02 2006-04-12 Novartis AG Genes regulated in ovarian cancer as prognostic and therapeutic targets
US20050002904A1 (en) * 2003-07-03 2005-01-06 Wary Kishore K. Uses of vascular endothelial growth factor and type I collagen inducible protein (VCIP)
EP3330875B1 (en) 2003-07-10 2021-12-01 Genomic Health, Inc. Expression profile algorithm and test for prognosing breast cancer recurrence
US20050130193A1 (en) 2003-09-10 2005-06-16 Luxon Bruce A. Methods for detecting, diagnosing and treating human renal cell carcinoma
JP2005211023A (ja) 2004-01-30 2005-08-11 Hayashibara Biochem Lab Inc 腎細胞癌の転移若しくは再発の可能性を予測する方法
US20070224596A1 (en) * 2004-04-09 2007-09-27 Mariana Nacht Compositions and methods for the modifying hypoxia induced gene regulation
US7871769B2 (en) 2004-04-09 2011-01-18 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
AU2005249446A1 (en) * 2004-05-27 2005-12-15 Vertex Pharmaceuticals Incorporated Biomarkers for monitoring inhibition of IMPDH pathway
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
WO2006066071A2 (en) * 2004-12-17 2006-06-22 Mayo Foundation For Medical Education And Research Prognosis of renal cell carcinoma
AU2006210794A1 (en) * 2005-02-01 2006-08-10 Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services Biomarkers for tissue status
RU2007129864A (ru) * 2005-02-18 2009-03-27 Вайет (Us) Фармакогеномные маркеры для прогнозирования солидных опухолей
WO2006124836A1 (en) 2005-05-13 2006-11-23 Duke University Gene expression signatures for oncogenic pathway deregulation
WO2006124022A1 (en) 2005-05-13 2006-11-23 Vanandel Research Institute Microarray gene expression profiling in subtypes of clear cell renal cell carcinoma
US20070037186A1 (en) * 2005-05-20 2007-02-15 Yuqiu Jiang Thyroid fine needle aspiration molecular assay
AU2006254834B2 (en) 2005-06-08 2012-09-20 Millennium Pharmaceuticals, Inc. Treatment of patients with cancer therapy
US20070105133A1 (en) 2005-06-13 2007-05-10 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070099209A1 (en) 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
ES2338699T3 (es) 2005-06-15 2010-05-11 Pfizer Limited Arilpirazoles sustituidos para uso contra parasitos.
JP5435529B2 (ja) 2005-09-02 2014-03-05 東レ株式会社 腎ガン診断、腎ガン患者予後予測のための組成物および方法
CN101292046B (zh) 2005-09-14 2013-03-13 人类遗传标记控股有限公司 健康状态的测定法
EP2332984A3 (en) 2005-09-30 2011-10-12 Universiteit Maastricht Tumor angiogenesis associated genes and a method for their identification
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
EP1960551A2 (en) 2005-12-01 2008-08-27 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
CA2633593A1 (en) 2005-12-16 2007-10-04 Genentech, Inc. Method for diagnosing, prognosing and treating glioma
US20080242606A1 (en) * 2006-06-06 2008-10-02 Zhong Jiang Use of IMP3 as a Prognostic Marker for Cancer
AU2007284724B2 (en) * 2006-08-10 2014-03-13 Millennium Pharmaceuticals, Inc. For the identification, assessment, and treatment of patients with cancer therapy
US8450057B2 (en) 2006-08-14 2013-05-28 The Brigham And Women's Hospital, Inc. Diagnostic tests using gene expression ratios
WO2008083098A1 (en) 2006-12-27 2008-07-10 The Johns Hopkins University Agents for reversing epigenetic silencing of genes
US20080286273A1 (en) 2007-05-02 2008-11-20 Siemens Medical Solutions Usa, Inc. Knowledge-Based Proliferation Signatures and Methods of Use
EP1990417A1 (en) 2007-05-11 2008-11-12 Universität Bayreuth Archaeal plasmid vector system
WO2009105640A1 (en) 2008-02-22 2009-08-27 Virginia Commonwealth University Signatures associated with rejection or recurrence of cancer
GB2512153B (en) 2008-11-17 2014-11-12 Veracyte Inc Methods and compositions of molecular profiling for disease diagnostics
CA2766703A1 (en) * 2009-06-26 2010-12-29 Noviogendix Research B.V. Molecular markers in kidney cancer
MX337650B (es) 2009-11-23 2016-03-14 Genomic Health Inc Metodos para predecir el desenlace clinico del cancer.
ES3027507T3 (en) 2010-01-11 2025-06-16 Genomic Health Inc Method to use gene expression to determine likelihood of clinical outcome of renal cancer
KR20140072014A (ko) 2011-06-16 2014-06-12 카리스 라이프 사이언스 룩셈부르크 홀딩스, 에스.에이.알.엘. 생물지표 조성물 및 방법
EP2748356A2 (en) 2011-08-22 2014-07-02 Somalogic, Inc. Renal cell carcinoma biomarkers and uses thereof

Also Published As

Publication number Publication date
DK3178944T3 (da) 2019-08-12
IL262100A (en) 2018-11-29
JP6286124B2 (ja) 2018-02-28
JP2016174600A (ja) 2016-10-06
EP2524055A4 (en) 2013-06-05
CA3128103C (en) 2025-11-18
MX2020009704A (es) 2020-10-07
EP3178944A3 (en) 2017-09-13
US9551034B2 (en) 2017-01-24
IL270151B (en) 2021-03-25
CA2783858C (en) 2021-09-14
US20170121780A1 (en) 2017-05-04
US20110171633A1 (en) 2011-07-14
JP7307602B2 (ja) 2023-07-12
US20240096451A1 (en) 2024-03-21
NZ719474A (en) 2018-07-27
JP6546214B2 (ja) 2019-07-17
EP2524055A2 (en) 2012-11-21
AU2011203977A1 (en) 2012-06-21
MX2012007882A (es) 2012-08-03
EP3831964A2 (en) 2021-06-09
JP2019162150A (ja) 2019-09-26
EP3029155A3 (en) 2016-08-31
WO2011085263A3 (en) 2012-01-12
MX375138B (es) 2025-03-06
IL280689A (en) 2021-03-25
CA3256492A1 (en) 2025-11-29
US20210166790A1 (en) 2021-06-03
JP7385630B2 (ja) 2023-11-22
US12412642B2 (en) 2025-09-09
US11776664B2 (en) 2023-10-03
JP2021177761A (ja) 2021-11-18
IL280689B (en) 2022-01-01
EP3831964A3 (en) 2021-10-20
IL251635B (en) 2018-04-30
IL219978A (en) 2017-04-30
ES3027507T3 (en) 2025-06-16
IL256335B (en) 2018-12-31
US20220051755A9 (en) 2022-02-17
JP2017148059A (ja) 2017-08-31
ES2741379T3 (es) 2020-02-10
IL251635A0 (en) 2017-06-29
CA3128103A1 (en) 2011-07-14
EP3831964B1 (en) 2025-04-16
EP3178944A2 (en) 2017-06-14
EP3178944B1 (en) 2019-05-15
NZ705645A (en) 2016-05-27
MX341866B (es) 2016-09-06
WO2011085263A2 (en) 2011-07-14
SG181806A1 (en) 2012-07-30
NZ617003A (en) 2015-04-24
IL219978A0 (en) 2012-07-31
EP3029155A2 (en) 2016-06-08
JP2013516195A (ja) 2013-05-13
EP3561078A1 (en) 2019-10-30
IL262100B (en) 2019-11-28
CA2783858A1 (en) 2011-07-14
AU2011203977B2 (en) 2015-02-05
US10892038B2 (en) 2021-01-12

Similar Documents

Publication Publication Date Title
NZ617003A (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
Wang et al. RETRACTED: Long non‐coding RNA CRNDE sponges miR‐384 to promote proliferation and metastasis of pancreatic cancer cells through upregulating IRS 1
NZ599194A (en) Methods to predict clinical outcome of cancer
Zhang et al. Circular RNA Circ_0000442 acts as a sponge of MiR-148b-3p to suppress breast cancer via PTEN/PI3K/Akt signaling pathway
Liao et al. microRNA-224 promotes cell proliferation and tumor growth in human colorectal cancer by repressing PHLPP1 and PHLPP2
Sun et al. Increased expression of lncRNA HULC indicates a poor prognosis and promotes cell metastasis in osteosarcoma
Wang et al. Upregulation of long noncoding RNA ZFAS1 predicts poor prognosis and prompts invasion and metastasis in colorectal cancer
Jiang et al. Knockdown of long noncoding RNA H19 sensitizes human glioma cells to temozolomide therapy
NZ593228A (en) Gene expression markers (inhba) for colorectal cancer prognosis
NZ722902A (en) Gene expression profile algorithm and test for determining prognosis of prostate cancer
Tsai et al. Clinical significance of microRNA-148a in patients with early relapse of stage II stage and III colorectal cancer after curative resection
Zheng et al. A sequence polymorphism in miR-608 predicts recurrence after radiotherapy for nasopharyngeal carcinoma
Shigeyasu et al. Exportin-5 functions as an oncogene and a potential therapeutic target in colorectal cancer
WO2014140933A8 (en) Method for the prognosis and treatment of cancer metastasis
Zhang et al. Serum microRNA‐150 predicts prognosis for early‐stage non‐small cell lung cancer and promotes tumor cell proliferation by targeting tumor suppressor gene SRCIN1
NZ627864A (en) Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status
Xu et al. The association of HOTAIR with the diagnosis and prognosis of gastric cancer and its effect on the proliferation of gastric cancer cells
Liu et al. Identifying Ki-67 specific miRNA–mRNA interactions in malignant astrocytomas
Chen et al. Low microRNA-139 expression associates with poor prognosis in patients with tumors: A meta-analysis
Zhang et al. Highly expressed long non-coding RNA DUXAP10 promotes proliferation of ovarian cancer.
Ou et al. UBA2 as a prognostic biomarker and potential therapeutic target in glioma
Mao et al. MicroRNA‐222 expression and its prognostic potential in non‐small cell lung cancer
Luan et al. Angiotensin II‐induced micro RNA‐21 culprit for non‐small‐cell lung adenocarcinoma
Guo et al. Comprehensive analysis to identify noncoding RNAs mediated upregulation of maternal embryonic leucine zipper kinase (MELK) correlated with poor prognosis in hepatocellular carcinoma
Liu et al. Investigation of the feasibility of NRAV as a biomarker for hepatocellular carcinoma

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE TITLE HAS BEEN CORRECTED TO TITLE: METHOD TO USE GENE EXPRESSION TO DETERMINE LIKELIHOOD OF CLINICAL OUTCOME OF RENAL CANCER; FILING DATE: 28 MAY 2012; STATUS: REJECTED; TITLE: METHOD TO USE GENE EXPRESSION TO DETERMINE LIKELIHOOD OF CLINICAL OUTCOME OF RENAL CANCER; FILING DATE: 23 OCT 2013; STATUS: REJECTED; TITLE: METHOD TO USE GENE EXPRESSION TO DETERMINE LIKELIHOOD OF CLINICAL OUTCOME OF RENAL CANCER; FILING DATE: 23 OCT 2013; STATUS: PROPOSED;

Effective date: 20131024

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2016 BY FB RICE

Effective date: 20150127

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2017 BY COMPUTER PACKAGES INC

Effective date: 20151218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2018 BY COMPUTER PACKAGES INC

Effective date: 20161220

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2019 BY COMPUTER PACKAGES INC

Effective date: 20171219

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2020 BY COMPUTER PACKAGES INC

Effective date: 20181218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2021 BY COMPUTER PACKAGES INC

Effective date: 20191218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2022 BY COMPUTER PACKAGES INC

Effective date: 20201218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2023 BY COMPUTER PACKAGES INC

Effective date: 20211217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2024 BY COMPUTER PACKAGES INC

Effective date: 20221217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2025 BY COMPUTER PACKAGES INC

Effective date: 20231217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2026 BY COMPUTER PACKAGES INC

Effective date: 20241217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2027 BY COMPUTER PACKAGES INC

Effective date: 20251217